Estimating morbidity due to stroke in Nigeria: a systematic review and meta-analysis.


Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
15 Jul 2019
Historique:
received: 04 02 2019
revised: 15 04 2019
accepted: 20 05 2019
pubmed: 1 6 2019
medline: 18 8 2020
entrez: 1 6 2019
Statut: ppublish

Résumé

The response to stroke in Nigeria is impaired by inadequate epidemiologic information. We sought to collate available evidence and estimate the incidence of stroke and prevalence of stroke survivors in Nigeria. Using random effects meta-analysis, we pooled nationwide and regional incidence and prevalence of stroke from the estimates reported in each study. Eleven studies met our selection criteria. The pooled crude incidence of stroke in Nigeria was 26.0 (12.8-39.0) /100,000 person-years, with this higher among men at 34.1 (9.7-58.4) /100,000, compared to women at 21.2 (7.4-35.0) /100,000. The pooled crude prevalence of stroke survivors in Nigeria was 6.7 (5.8-7.7) /1000 population, with this also higher among men at 6.4 (5.1-7.6) /1000, compared to women at 4.4 (3.4-5.5) /1000. In the period 2000-2009, the incidence of stroke in Nigeria was 24.3 (95% CI: 11.9-36.8) per 100,000, with this increasing to 27.4 (95% CI: 2.2-52.7) per 100,000 from 2010 upwards. The prevalence of stroke survivors increased minimally from 6.0 (95% CI: 4.6-7.5) per 1000 to 7.5 (95% CI: 5.8-9.1) per 1000 over the same period. The prevalence of stroke survivors was highest in the South-south region at 13.4 (9.1-17.8) /100,000 and among rural dwellers at 10.8 (7.5-14.1) /100,000. Although study period does not appear to contribute substantially to variations in stroke morbidity in Nigeria, an increasing number of new cases compared to survivors may be due in part to limited door-door surveys, or possibly reflects an increasing mortality from stroke in the country.

Sections du résumé

BACKGROUND BACKGROUND
The response to stroke in Nigeria is impaired by inadequate epidemiologic information. We sought to collate available evidence and estimate the incidence of stroke and prevalence of stroke survivors in Nigeria.
METHODS METHODS
Using random effects meta-analysis, we pooled nationwide and regional incidence and prevalence of stroke from the estimates reported in each study.
RESULTS RESULTS
Eleven studies met our selection criteria. The pooled crude incidence of stroke in Nigeria was 26.0 (12.8-39.0) /100,000 person-years, with this higher among men at 34.1 (9.7-58.4) /100,000, compared to women at 21.2 (7.4-35.0) /100,000. The pooled crude prevalence of stroke survivors in Nigeria was 6.7 (5.8-7.7) /1000 population, with this also higher among men at 6.4 (5.1-7.6) /1000, compared to women at 4.4 (3.4-5.5) /1000. In the period 2000-2009, the incidence of stroke in Nigeria was 24.3 (95% CI: 11.9-36.8) per 100,000, with this increasing to 27.4 (95% CI: 2.2-52.7) per 100,000 from 2010 upwards. The prevalence of stroke survivors increased minimally from 6.0 (95% CI: 4.6-7.5) per 1000 to 7.5 (95% CI: 5.8-9.1) per 1000 over the same period. The prevalence of stroke survivors was highest in the South-south region at 13.4 (9.1-17.8) /100,000 and among rural dwellers at 10.8 (7.5-14.1) /100,000.
CONCLUSION CONCLUSIONS
Although study period does not appear to contribute substantially to variations in stroke morbidity in Nigeria, an increasing number of new cases compared to survivors may be due in part to limited door-door surveys, or possibly reflects an increasing mortality from stroke in the country.

Identifiants

pubmed: 31151064
pii: S0022-510X(19)30236-9
doi: 10.1016/j.jns.2019.05.020
pmc: PMC6650746
mid: NIHMS1530730
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

136-144

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NHLBI NIH HHS
ID : K99 HL141678
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Références

BMJ. 2001 Jul 7;323(7303):42-6
pubmed: 11440947
Natl Med J India. 2004 Mar-Apr;17(2):86-95
pubmed: 15141602
Trop Doct. 2005 Apr;35(2):104-6
pubmed: 15970038
Neuroepidemiology. 2007;28(4):216-23
pubmed: 17851261
Niger J Clin Pract. 2008 Mar;11(1):22-4
pubmed: 18689134
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Vasc Health Risk Manag. 2009;5:745-50
pubmed: 19774215
J Vasc Nurs. 2009 Dec;27(4):98-102
pubmed: 19914570
J Diabetes Sci Technol. 2011 Jul 01;5(4):918-27
pubmed: 21880235
ISRN Neurol. 2012;2012:468706
pubmed: 22474601
Stroke. 2013 Jul;44(7):2064-89
pubmed: 23652265
J Neurol Sci. 2013 Aug 15;331(1-2):43-7
pubmed: 23726277
J Card Fail. 2014 Jan;20(1):45-52
pubmed: 24269854
Lancet. 2014 Jan 18;383(9913):245-54
pubmed: 24449944
Int J Cancer. 2014 Nov 1;135(9):2173-82
pubmed: 24658866
PLoS One. 2014 Jun 26;9(6):e100724
pubmed: 24967899
Vasc Health Risk Manag. 2014 Jun 24;10:375-88
pubmed: 25028556
BMC Public Health. 2014 Jul 31;14:776
pubmed: 25081994
Lancet Glob Health. 2014 Mar;2(3):e174-81
pubmed: 25102850
J Hypertens. 2015 Feb;33(2):230-42
pubmed: 25380154
J Stroke Cerebrovasc Dis. 2015 Apr;24(4):771-7
pubmed: 25680665
Cardiovasc J Afr. 2015 Mar-Apr;26(2 Suppl 1):S27-38
pubmed: 25962945
J Hum Hypertens. 2016 Apr;30(4):285-91
pubmed: 26016595
Pan Afr Med J. 2015 Jan 13;20:33
pubmed: 26029322
Am J Hypertens. 2016 Aug;29(8):925-33
pubmed: 26884135
J Neurol Sci. 2016 May 15;364:68-76
pubmed: 27084220
Lancet Neurol. 2016 Aug;15(9):913-924
pubmed: 27291521
Bull World Health Organ. 2016 Sep 1;94(9):634-634A
pubmed: 27708464
J Neurol Sci. 2017 Jan 15;372:262-269
pubmed: 28017225
Circ Res. 2017 Feb 3;120(3):439-448
pubmed: 28154096
BMJ Open. 2017 Mar 24;7(3):e013650
pubmed: 28341688
BMJ Open. 2017 May 11;7(5):e015424
pubmed: 28495817
Nutr Rev. 2017 Jun 1;75(6):405-419
pubmed: 28969358
BMC Health Serv Res. 2018 Mar 22;18(1):197
pubmed: 29566692
BMC Med Res Methodol. 2018 May 21;18(1):44
pubmed: 29783954
Prim Care Diabetes. 2018 Oct;12(5):393-408
pubmed: 30076075
J Neurol Sci. 2018 Nov 15;394:6-13
pubmed: 30196133
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833

Auteurs

Davies Adeloye (D)

Centre for Global Health Research, Usher Institute, University of Edinburgh, UK; RcDavies Evidence-based Medicine, Lagos, Nigeria. Electronic address: bummyadeloy@gmail.com.

Martinsixtus Ezejimofor (M)

British Association of Dermatologists, London, UK.

Asa Auta (A)

School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Fylde Road, Preston, UK.

Rex G Mpazanje (RG)

WHO Nigeria Country Office, Abuja, Nigeria.

Nnenna Ezeigwe (N)

Federal Ministry of Health, Abuja, Nigeria.

Evelyn N Ngige (EN)

Federal Ministry of Health, Abuja, Nigeria.

Michael O Harhay (MO)

Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine University of Pennsylvania Philadelphia, Pennsylvania, USA; Palliative and Advanced Illness Research (PAIR) Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Wondimagegnehu Alemu (W)

International Health Consultancy, Atlanta, Georgia, USA.

Isaac F Adewole (IF)

Federal Ministry of Health, Abuja, Nigeria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH